Table 1.
Cases, burden of disease, and cost-effectiveness of high-risk prioritization of COVID-19 vaccination in Colombia.
| Outcomes | No vaccination | High-risk prioritization | No prioritization |
|---|---|---|---|
| Cases and deaths, n (/100 000 pop.) | |||
| Cases | 204 988 (401.28) | 114 532 (224.21) | 162 779 (318.65) |
| Hospitalization | 77 450 (151.61) | 41 560 (81.36) | 61 165 (119.74) |
| Critical care admissions | 36 134 (70.73) | 11 129 (21.79) | 24 965 (48.87) |
| Deaths | 36 163 (70.79) | 14 444 (28.28) | 24 082 (47.14) |
| Burden of disease | |||
| Costs, US$ in millions | $163.54 | $419.29 | $470.55 |
| DALYs | 294 751 | 218 166 | 235 979 |
| Avoided costs, US$ in millions | Ref. | $255.74 | $307.00 |
| Avoided DALYs | Ref. | 76 585.64 | 58 771.86 |
| Incremental cost-effectiveness ratio | Ref. | $3339.33 | $5223.66 |
DALY indicates disability-adjusted life-year; pop., population; Ref., reference.